Local photodynamic therapy with Zn(II)-phthalocyanine in an experimental model of intimal hyperplasia
- PMID: 11154089
- DOI: 10.1016/s1011-1344(00)00083-x
Local photodynamic therapy with Zn(II)-phthalocyanine in an experimental model of intimal hyperplasia
Abstract
Photodynamic therapy (PDT) appears to be a novel promising modality to prevent intimal hyperplasia (IH) and restenosis after angioplasty. Local PDT, that consists of local delivery of photosensitizing agents followed by intraluminal local irradiation, represents a recent advancement. This methodology requires optimization in order to achieve the best prompt outcome especially in terms of pharmacokinetics of the photosensitizing agent. We studied the pharmacokinetic properties by using the photosensitizing agent Zn(II)-phthalocyanine (ZnPc), locally released by a channeled balloon. The efficacy of local PDT in reducing IH was evaluated in an experimental rabbit model of arterial injury. The maximum accumulation of ZnPc was found at 30 min: the injured portion of the artery gave a ZnPc recovery of 1.18 micromol/mg, as compared with undetectable amounts of ZnPc in the non injured arteries; within 90 min after the local delivery, clearance of the agent was almost complete. Local PDT produced an effective reduction of IH in our vascular injury model: at 7, 14, 21 and 28 days IH and intima/media ratio (IMR) was significantly reduced as compared with balloon injured arteries. The local delivery of ZnPc showed favourable pharmacokinetic properties, that allow the performance of PDT immediately after the vascular injury. Local PDT performed in these conditions represents a promising approach to prevent IH after balloon injury. Further studies are needed to better clarify the biological response of the injured arterial wall to local PDT.
Similar articles
-
Endovascular photodynamic therapy using mono-L-aspartyl-chlorin e6 to inhibit Intimal hyperplasia in balloon-injured rabbit arteries.Lasers Surg Med. 2001;28(4):381-8. doi: 10.1002/lsm.1066. Lasers Surg Med. 2001. PMID: 11344521
-
Photodynamic therapy inhibition of experimental intimal hyperplasia: acute and chronic effects.J Vasc Surg. 1994 Feb;19(2):321-9; discussion 329-31. doi: 10.1016/s0741-5214(94)70107-5. J Vasc Surg. 1994. PMID: 8114192
-
Inhibition of intimal hyperplasia in balloon injured arteries with adjunctive phthalocyanine sensitised photodynamic therapy.Eur J Vasc Endovasc Surg. 1996 Jan;11(1):19-28. doi: 10.1016/s1078-5884(96)80130-4. Eur J Vasc Endovasc Surg. 1996. PMID: 8564482
-
Porphyrin-photosensitized processes: their applications in the prevention of arterial restenosis.Cardiovasc Hematol Agents Med Chem. 2007 Oct;5(4):278-88. doi: 10.2174/187152507782109908. Cardiovasc Hematol Agents Med Chem. 2007. PMID: 17979690 Review.
-
Tetra-triethyleneoxysulfonyl substituted zinc phthalocyanine for photodynamic cancer therapy.Photodiagnosis Photodyn Ther. 2016 Mar;13:148-157. doi: 10.1016/j.pdpdt.2015.07.001. Epub 2015 Jul 7. Photodiagnosis Photodyn Ther. 2016. PMID: 26162500 Review.
Cited by
-
Therapeutic strategies based on non-ionizing radiation to prevent venous neointimal hyperplasia: the relevance for stenosed arteriovenous fistula, and the role of vascular compliance.Front Cardiovasc Med. 2024 Feb 5;11:1356671. doi: 10.3389/fcvm.2024.1356671. eCollection 2024. Front Cardiovasc Med. 2024. PMID: 38374996 Free PMC article. Review.
-
Large animal models for investigating the applications of photodynamic therapy.Zool Res. 2025 May 18;46(3):551-575. doi: 10.24272/j.issn.2095-8137.2024.445. Zool Res. 2025. PMID: 40259735 Free PMC article. Review.
-
Photodynamic therapy: shedding light on restenosis.Heart. 2001 Dec;86(6):612-8. doi: 10.1136/heart.86.6.612. Heart. 2001. PMID: 11711449 Free PMC article. Review. No abstract available.
-
Light-induced Difference Terahertz Spectroscopy.J Biol Phys. 2003 Jun;29(2-3):135-9. doi: 10.1023/A:1024432507126. J Biol Phys. 2003. PMID: 23345829 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources